RecruitingNot Applicable

Elongation Longitudinal Decoaptation Ostéo-Articulaire Versus Active Isolated Stretching on Median Nerve Mobility and Pain in Patient With Upper Limb Overuse Syndrome

Pakistan84 participantsStarted 2026-07-10

Plain-language summary

Upper-limb overuse syndrome (ULOS) often arises from repetitive loading, altering cervical biomechanics and increased median-nerve mechano sensitivity. Elongation longitudinal decoaptation ostéo-articulaire (ELDOA) at C5-C6 improves segmental decompression and neural sliding, while Active isolated stretching (AIS) enhances soft tissue elasticity and neuro dynamic glide. Currently no direct comparison exists between these two methods in literature. Study aims to compare ELDOA (C5-C6 specific) and AIS in patients with ULOS for checking effects on median nerve mobility and pain. This research will be conducted as a randomized clinical trial involving 84 participants (42 in each group). Adults aged 20-50 years with diagnosis of ULOS, symptom duration 3- months (12 weeks) will be included in the study. While Neurological or rheumatologic conditions, recent corticosteroid injections, recent cervical or major upper limb surgery, and ongoing neural mobilization-focused physical therapy are among the exclusions. After meeting the inclusion and exclusion criteria and obtaining written and verbal consent from the participants. Participants will be randomly assigned to either the AIS or ELDOA groups and will receive 3 sessions per week for 3 weeks with baseline hot pack. Group A will perform diaphragmatic breathing with ELDOA targeting C5-C6, whereas Group B will engage in AIS on muscles that cause median-nerve tension. Pain intensity, upper limb function and median nerve mobility are outcome measures that will be assessed using tools NPRS, QuickDASH and ULTT1. Data will be analyzed using the 2024 SPSS.

Who can participate

Age range

20 Years – 50 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * All adult age group (20-50 years) patients with clinical symptoms and signs of upper limb overuse syndrome with median nerve were included in the study (Latif et al., 2022). * Participants included individuals engaged in repetitive upper-limb activities, such as office workers, manual laborers, athletes and students, who demonstrated median nerve involvement associated with repetitive task performance (Descatha et al., 2017). * Persistent pain in the upper limb, pain intensity score from 3-7 on the Numeric pain rating scale (NPRS), discomfort and functional limitations in daily activities, occupational tasks or recreational activities were deemed to be indications of eligibility for participation in the study (Hawker et al., 2011). * Participants with persistent nature symptoms (3 months or more than 3 months) are included in the study to secure homogenous study population (Nicholas et al., 2019). * Willing to give their informed consent and take part. Exclusion Criteria: * Trauma, surgery, fracture or dislocation of the upper limb in the last six months or less were excluded to minimize the possibility of studying the acute tissue healing on the results of this study (Cools et al., 2021). * Other neurological conditions (e.g., peripheral or central nervous system disorders, systemic neuropathies, cervical radiculopathy, or other neurological disorders) were excluded for participation (Padua et al., 2020). * The potential effect of rheumatologic or in…

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Pain intensity

Timeframe: 3 weeks

Functional status/ Disability

Timeframe: 3 weeks

Nerve mobility

Timeframe: 3 weeks

Trial details

NCT IDNCT07703332

SponsorUniversity of Faisalabad

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-08-20

Contact for this trial

Dr. Rubina Zulfqar

+923414291664 drubinazulfqar355@gmail.com

View on ClinicalTrials.gov More Upper Limb Overuse Syndrome trials

Plain-language summary

Who can participate

Age range

20 Years – 50 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.